세계의 항감염제 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)
Anti-Infective Agents Market Size, Share & Trends Analysis Report By Type (Antibacterial, Antiviral, Antifungal & Antiparasitic), By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
상품코드
:
1611183
리서치사
:
Grand View Research, Inc.
발행일
:
2024년 11월
페이지 정보
:
영문 130 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
항감염제 시장의 성장과 동향 :
Grand View Research, Inc.의 최신 리포트에 따르면 세계의 항감염제 시장 규모는 2025-2030년에 CAGR 1.61%로 확대하며, 2030년에는 1,449억 6,000만 달러에 달할 것으로 추정됩니다. 전염병 증가는 지난 수십년간 지역사회의 행동 패턴이 크게 변화한 것을 반영합니다. 사회 변화와 의료 전문가와 환자들의 인식이 높아지면서 성장을 가속하고 있습니다.
세계보건기구(WHO)와 질병통제예방센터(CDC)와 같은 치료 기관은 전염병의 치명적인 영향과 조기 치료의 중요성에 대한 인식을 확산하기 위해 적극적으로 노력하고 있습니다.에 대한 인식을 확산하고 치료를 강화하기 위해 국가보건부(NHM)와 협력하고 있습니다.
그러나 효능-효과를 높인 신규 치료제의 도입과 2018년 시중 획득 세균성 폐렴(CABP) 치료제로 오마다사이클린이 상용화되는 등 파이프라인 제품의 상용화가 항감염제 시장의 성장을 가속할 것으로 예상됩니다.
항감염제 시장 보고서의 하이라이트
- HIV 치료제 비클리비록과 같은 새로운 강력한 항바이러스제와 관련된 높은 가격으로 인해 2024년 시장 점유율은 50.9%로 항바이러스제가 가장 큰 부문으로 추정됩니다.
- 항바이러스제는 항감염제 시장의 중요한 컴포넌트로 주로 바이러스 감염의 치료와 예방에 사용됩니다.
- 2024년 8월, 시오노이제약은 신규 시데로포아 세팔로스포린계 항생제인 세피데로콜의 신약허가신청(NDA)이 중국 의약품평가센터로부터 승인받았다고 발표했습니다. 세피데로콜은 다제내성균을 포함한 그람음성균을 표적으로 하며, 임상 3상 시험에서 이미페넴/실라스타틴 대비 우수한 효능을 보였습니다.
- 2024년에는 병원내 약국이 48.5%의 가장 높은 매출 점유율로 시장을 장악할 것으로 예상되며, E-Commerce는 예측 기간 중 가장 빠르게 성장하는 부문이 될 것으로 보입니다.
- 북미가 2024년 전체 매출의 38.1%로 가장 큰 점유율을 차지하며 세계 시장을 주도할 것으로 보입니다. 소아 및 성인 모두에서 병원내 감염을 포함한 감염성 질환의 높은 유병률과 이로 인한 항생제 과다 사용, 비처방 항감염 약품에 대한 접근성 증가가 주요 촉진요인으로 작용할 것으로 보입니다.
- 아시아태평양은 신약에 대한 미충족 수요가 높고, 의료 인프라의 급속한 개선과 의료진 및 환자의 인식이 높아짐에 따라 가장 빠르게 성장하는 지역 중 하나입니다.
- 효과적인 질병 관리를 위해서는 신제품 개발, M&A, 공동 개발, 사업 확장 등 다양한 장기 전략이 필요합니다. 예를 들어 2024년 1월 Basilea Pharmaceutica는 Spexis AG의 전임상 항생제 프로그램 인수를 발표했습니다.
목차
제1장 조사 방법과 범위
제2장 개요
제3장 항감염제 시장 변수, 동향, 범위
- 시장 계통 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 항감염제 시장 분석 툴
- Porter's Five Forces 분석
- PESTLE 분석
제4장 항감염제 시장 - 부문 분석 : 유형별(2018-2030년)
제5장 항감염제 시장 - 부문 분석 : 투여 경로별(2018-2030년)
- 항감염제 시장 : 투여 경로의 변동 분석
- 투여 경로별
제6장 항감염제 시장 - 부문 분석 : 유통 채널별(2018-2030년)
- 항감염제 시장 : 유통 채널의 변동 분석
- 유통 채널별
제7장 항감염제 시장 : 유형, 투여 경로, 유통 채널별 지역 추정·동향 분석
- 항감염제 시장 : 지역별 전망
- 북미
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제8장 경쟁 구도
- 참여 기업
- 참여 기업의 개요
- 재무 실적
- 제품 벤치마킹
- 기업의 시장 포지셔닝 분석 : 2024년
- 주요 기업 개요
- Pfizer Inc.
- Bayer AG
- AbbVie
- Gilead Sciences, Inc.
- Bristol-Myers Squibb
- Merck &Co., Inc.
- Sandoz International GmbH
- B. Braun SE
- Xellia Pharmaceuticals
- Mankind Pharma
- AstraZeneca
- Boehringer Ingelheim International GmbH
제9장 결론
KSA
영문 목차
Anti-Infective Agents Market Growth & Trends:
The global anti-infective agents market size is estimated to reach USD 144.96 billion by 2030, expanding at a CAGR of 1.61% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.
Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongstpeople regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.
However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.
Anti-Infective Agents Market Report Highlights:
- Antiviral was estimated to be the largest segment with a market share of 50.9% in 2024 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
- Antiviral segment dominated the market with a 50.9% share in 2024. Antiviral drugs are crucial components of the anti-infective agents market, primarily used in the treatment and prevention of viral infections
- In August 2024, Shionogi & Co. announced that its New Drug Application (NDA) for cefiderocol, a novel siderophore cephalosporin antibiotic, has been accepted for review in China by the Center for Drug Evaluation. Cefiderocol targets gram-negative bacteria, including multidrug-resistant strains, and has demonstrated superior efficacy in a Phase III trial compared to imipenem/cilastatin.
- Hospital pharmacy dominated the market with the highest revenue share of 48.5% in 2024 while e-commerce is expected to be the fastest-growing segment during the forecast period
- North America dominated the global industry in 2024 and accounted for the largest share of 38.1% of the overall revenue. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers
- Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients
- Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in January 2024, Basilea Pharmaceutica announced its acquisition of a preclinical antibiotics program from Spexis AG.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation
- 1.1.1 Market Definitions
- 1.1.2 Estimates And Forecast Timeline
- 1.2 Objectives
- 1.2.1 Objective - 1
- 1.2.2 Objective - 2
- 1.2.3 Objective - 3
- 1.3 Research Methodology
- 1.4 Information Procurement
- 1.4.1 Purchased Database
- 1.4.2 Gvr's Internal Database
- 1.4.3 Secondary Sources
- 1.4.4 Primary Research
- 1.5 Information Or Data Analysis
- 1.5.1 Data Analysis Models
- 1.6 Market Formulation & Validation
- 1.7 Model Details
- 1.7.1 Epidemiology-Based Market Analysis
- 1.7.1.1 Approach 1: Epidemiology-Based Approach
- 1.7.1.2 Approach 2: Commodity Flow Approach
- 1.7.1.3 Approach 2: Revenue share analysis Using Bottom-up Approach
- 1.8 List of Secondary Sources
- 1.9 List of Abbreviations
- 1.10 Research Assumptions
Chapter 2 Executive Summary
- 2.1 Market Snapshot
- 2.2 By Type and Route of Administration Snapshot
- 2.3 By Distribution Channel Segment Snapshot
- 2.4 Competitive Landscape Snapshot
Chapter 3 Anti-infective Agents Market Variables, Trends, and Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Ancillary Market Outlook
- 3.2 Market Dynamics
- 3.2.1 Market Driver Analysis
- 3.2.1.1 Increasing Incidence Of Targeted Diseases
- 3.2.1.2 Growing Investments On R&D Activities Of Anti-Infective Drugs
- 3.2.1.3 Rise In Initiatives For The Awareness Of Infectious Diseases
- 3.2.2 Market Restraint Analysis
- 3.2.2.1 Emergence of Resistance to Anti-infective Drugs and Adverse Effects Associated with them
- 3.3 Anti-infective Agents Market Analysis Tools
- 3.3.1 Porter's Five Forces Analysis
- 3.3.2 Pestle Analysis
Chapter 4 Anti-infective Agents Market - Segment Analysis, by Type, 2018 - 2030 (USD Million)
- 4.1 Anti-infective Agents Market: Type Movement Analysis
- 4.2 Anti-infective Agents Market Estimates & Forecast, By Type (USD Million)
- 4.2.1 Antibacterials
- 4.2.1.1 Cephalosporins
- 4.2.1.2 Penicillin
- 4.2.1.3 Fluoroquinolones
- 4.2.1.4 Macrolides
- 4.2.1.5 Carbapenem
- 4.2.1.6 Others
- 4.2.2 Antivirals
- 4.2.3 Antifungals
- 4.2.3.1 Azoles
- 4.2.3.2 Echinocandins
- 4.2.3.3 Polyenes
- 4.2.3.4 Others
Chapter 5 Anti-infective Agents Market - Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)
- 5.1 Anti-infective Agents Market: Route of Administration Movement Analysis
- 5.2 Anti-infective Agents Market Estimates & Forecast, By Route of Administration (USD Million)
- 5.2.1 Topical
- 5.2.2 Oral
- 5.2.3 Parental
- 5.2.4 Others
Chapter 6 Anti-infective Agents Market - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
- 6.1 Anti-infective Agents Market: Distribution Channel Movement Analysis
- 6.2 Anti-infective Agents Market Estimates & Forecast, By Distribution Channel (USD Million)
- 6.2.1 Hospital Pharmacies
- 6.2.2 Retail Pharmacies
- 6.2.3 Others
Chapter 7 Anti-infective Agents Market: Regional Estimates and Trend Analysis by Type, Route of Administration, and Distribution Channel
- 7.1 Anti-infective Agents Market: Regional Outlook
- 7.2 North America
- 7.2.1 North America Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.2.2 U.S.
- 7.2.2.1 Key Country Dynamics
- 7.2.2.2 U.S. Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2.3 Competitive/Market Scenario
- 7.2.2.4 Regulatory Framework
- 7.2.2.5 Reimbursement Scenario
- 7.2.3 Canada
- 7.2.3.1 Key Country Dynamics
- 7.2.3.2 Canada Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3.3 Competitive/Market Scenario
- 7.2.3.4 Regulatory Framework
- 7.2.3.5 Reimbursement Scenario
- 7.2.4 Mexico
- 7.2.4.1 Key Country Dynamics
- 7.2.4.2 Mexico Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4.3 Competitive/Market Scenario
- 7.2.4.4 Regulatory Framework
- 7.2.4.5 Reimbursement Scenario
- 7.3 Europe
- 7.3.1 Europe Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3.2 UK
- 7.3.2.1 Key Country Dynamics
- 7.3.2.2 UK Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2.3 Competitive/Market Scenario
- 7.3.2.4 Regulatory Framework
- 7.3.2.5 Reimbursement Scenario
- 7.3.3 Germany
- 7.3.3.1 Key Country Dynamics
- 7.3.3.2 Germany Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3.3 Competitive/Market Scenario
- 7.3.3.4 Regulatory Framework
- 7.3.3.5 Reimbursement Scenario
- 7.3.4 France
- 7.3.4.1 Key Country Dynamics
- 7.3.4.2 France Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4.3 Competitive/Market Scenario
- 7.3.4.4 Regulatory Framework
- 7.3.4.5 Reimbursement Scenario
- 7.3.5 Italy
- 7.3.5.1 Key Country Dynamics
- 7.3.5.2 Italy Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5.3 Competitive/Market Scenario
- 7.3.5.4 Regulatory Framework
- 7.3.5.5 Reimbursement Scenario
- 7.3.6 Spain
- 7.3.6.1 Key Country Dynamics
- 7.3.6.2 Spain Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6.3 Competitive/Market Scenario
- 7.3.6.4 Regulatory Framework
- 7.3.6.5 Reimbursement Scenario
- 7.3.7 Denmark
- 7.3.7.1 Key Country Dynamics
- 7.3.7.2 Denmark Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7.3 Competitive/Market Scenario
- 7.3.7.4 Regulatory Framework
- 7.3.7.5 Reimbursement Scenario
- 7.3.8 Sweden
- 7.3.8.1 Key Country Dynamics
- 7.3.8.2 Sweden Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8.3 Competitive/Market Scenario
- 7.3.8.4 Regulatory Framework
- 7.3.8.5 Reimbursement Scenario
- 7.3.9 Norway
- 7.3.9.1 Key Country Dynamics
- 7.3.9.2 Norway Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9.3 Competitive/Market Scenario
- 7.3.9.4 Regulatory Framework
- 7.3.9.5 Reimbursement Scenario
- 7.3.10 Rest Of Europe Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4 Asia Pacific
- 7.4.1 Asia Pacific Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.2 Japan
- 7.4.2.1 Key Country Dynamics
- 7.4.2.2 Japan Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.2.3 Competitive/Market Scenario
- 7.4.2.4 Regulatory Framework
- 7.4.2.5 Reimbursement Scenario
- 7.4.3 China
- 7.4.3.1 Key Country Dynamics
- 7.4.3.2 China Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.3.3 Competitive/Market Scenario
- 7.4.3.4 Regulatory Framework
- 7.4.3.5 Reimbursement Scenario
- 7.4.4 India
- 7.4.4.1 Key Country Dynamics
- 7.4.4.2 India Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.4.3 Competitive/Market Scenario
- 7.4.4.4 Regulatory Framework
- 7.4.4.5 Reimbursement Scenario
- 7.4.5 Australia
- 7.4.5.1 Key Country Dynamics
- 7.4.5.2 Australia Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.5.3 Competitive/Market Scenario
- 7.4.5.4 Regulatory Framework
- 7.4.5.5 Reimbursement Scenario
- 7.4.6 Thailand
- 7.4.6.1 Key Country Dynamics
- 7.4.6.2 Thailand Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.6.3 Competitive/Market Scenario
- 7.4.6.4 Regulatory Framework
- 7.4.6.5 Reimbursement Scenario
- 7.4.7 South Korea
- 7.4.7.1 Key Country Dynamics
- 7.4.7.2 South Korea Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.7.3 Competitive/Market Scenario
- 7.4.7.4 Regulatory Framework
- 7.4.7.5 Reimbursement Scenario
- 7.4.8 Rest Of Asia Pacific Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5 Latin America
- 7.5.1 Latin America Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.2 Brazil
- 7.5.2.1 Key Country Dynamics
- 7.5.2.2 Brazil Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2.3 Competitive/Market Scenario
- 7.5.2.4 Regulatory Framework
- 7.5.2.5 Reimbursement Scenario
- 7.5.3 Argentina
- 7.5.3.1 Key Country Dynamics
- 7.5.3.2 Argentina Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3.3 Competitive/Market Scenario
- 7.5.3.4 Regulatory Framework
- 7.5.3.5 Reimbursement Scenario
- 7.5.4 Rest Of Latin America Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6 MEA
- 7.6.1 MEA Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.2 South Africa
- 7.6.2.1 Key Country Dynamics
- 7.6.2.2 South Africa Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2.3 Competitive/Market Scenario
- 7.6.2.4 Regulatory Framework
- 7.6.2.5 Reimbursement Scenario
- 7.6.3 Saudi Arabia
- 7.6.3.1 Key Country Dynamics
- 7.6.3.2 Saudi Arabia Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3.3 Competitive/Market Scenario
- 7.6.3.4 Regulatory Framework
- 7.6.3.5 Reimbursement Scenario
- 7.6.4 UAE
- 7.6.4.1 Key Country Dynamics
- 7.6.4.2 UAE Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4.3 Competitive/Market Scenario
- 7.6.4.4 Regulatory Framework
- 7.6.4.5 Reimbursement Scenario
- 7.6.5 Kuwait
- 7.6.5.1 Key Country Dynamics
- 7.6.5.2 Kuwait Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5.3 Competitive/Market Scenario
- 7.6.5.4 Regulatory Framework
- 7.6.5.5 Reimbursement Scenario
- 7.6.6 Rest Of MEA Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Competitive Landscape
- 8.1 Participant Categorization
- 8.2 Participant's Overview
- 8.3 Financial Performance
- 8.4 Product Benchmarking
- 8.5 Company Market Positioning Analysis, 2024
- 8.6 Key Company Profiles
- 8.6.1. Pfizer Inc.
- 8.6.1.1. Company overview
- 8.6.1.2. Financial performance
- 8.6.1.3. Product benchmarking
- 8.6.1.4. Strategic initiatives
- 8.6.2. Bayer AG
- 8.6.2.1. Company overview
- 8.6.2.2. Financial performance
- 8.6.2.3. Product benchmarking
- 8.6.2.4. Strategic initiatives
- 8.6.3. AbbVie
- 8.6.3.1. Company overview
- 8.6.3.2. Financial performance
- 8.6.3.3. Product benchmarking
- 8.6.3.4. Strategic initiatives
- 8.6.4. Gilead Sciences, Inc.
- 8.6.4.1. Company overview
- 8.6.4.2. Financial performance
- 8.6.4.3. Product benchmarking
- 8.6.4.4. Strategic initiatives
- 8.6.5. Bristol-Myers Squibb
- 8.6.5.1. Company overview
- 8.6.5.2. Financial performance
- 8.6.5.3. Product benchmarking
- 8.6.5.4. Strategic initiatives
- 8.6.6. Merck & Co., Inc.
- 8.6.6.1. Company overview
- 8.6.6.2. Financial performance
- 8.6.6.3. Product benchmarking
- 8.6.6.4. Strategic initiatives
- 8.6.7. Sandoz International GmbH
- 8.6.7.1. Company overview
- 8.6.7.2. Financial performance
- 8.6.7.3. Product benchmarking
- 8.6.7.4. Strategic initiatives
- 8.6.8. B. Braun SE
- 8.6.8.1. Company overview
- 8.6.8.2. Financial performance
- 8.6.8.3. Product benchmarking
- 8.6.8.4. Strategic initiatives
- 8.6.9. Xellia Pharmaceuticals
- 8.6.9.1. Company overview
- 8.6.9.2. Financial performance
- 8.6.9.3. Product benchmarking
- 8.6.9.4. Strategic initiatives
- 8.6.10. Mankind Pharma
- 8.6.10.1. Company overview
- 8.6.10.2. Financial performance
- 8.6.10.3. Product benchmarking
- 8.6.10.4. Strategic initiatives
- 8.6.11. AstraZeneca
- 8.6.11.1. Company overview
- 8.6.11.2. Financial performance
- 8.6.11.3. Product benchmarking
- 8.6.11.4. Strategic initiatives
- 8.6.12. Boehringer Ingelheim International GmbH
- 8.6.12.1. Company overview
- 8.6.12.2. Financial performance
- 8.6.12.3. Product benchmarking
- 8.6.12.4. Strategic initiatives
Chapter 9 Conclusion
관련자료
